Science 37 taps a SPAC to go public, with siteless trial specialist valued at a cool $1B

Retrieved on: 2021-05-07 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Science 37 taps a SPAC to go public, with siteless trial specialist valued at a cool $1B. View article details on hiswai:

Excerpt

... Capital (Novartis Pharma); LifeSci Venture Partners; Lux Capital; Mubadala Capital, the asset management arm of Mubadala Investment Company; ...

Article found on: www.fiercebiotech.com